Oligomerization of GPCRs involved in endocrine regulation

Journal of Molecular Endocrinology

Volumn 57, Issue 1, 2016, Pages R59-R80

  Kleinau, Gunnar ^a   Müller, Anne ^a   Biebermann, Heike ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Dimers; Endocrine diseases; Endocrine regulation; G protein coupled receptors; Heteromers; Heterooligomerization; Homomers; Homooligomerization; Oligomers; Signaling

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; G PROTEIN COUPLED RECEPTOR; INTRACELLULAR INTERACTING PROTEIN; ION CHANNEL; MEMBRANE PROTEIN; OLIGOMER; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; CARRIER PROTEIN; HORMONE; LIGAND; PROTEIN BINDING;

ENDOCRINE FUNCTION; ENDOCRINE REGULATION; HUMAN; HYPOPHYSIS THYROID SYSTEM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; MOLECULAR BIOLOGY; MOLECULAR PATHOLOGY; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; DISEASE PREDISPOSITION; ENDOCRINE GLAND; GENE EXPRESSION REGULATION; GENETICS; GONAD; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; MULTIGENE FAMILY; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CARRIER PROTEINS; DISEASE SUSCEPTIBILITY; ENDOCRINE GLANDS; GENE EXPRESSION REGULATION; GONADS; HORMONES; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LIGANDS; MULTIGENE FAMILY; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84976615624     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-16-0049     Document Type: Review

References (275)

1. AbdAlla S, Lother H & Quitterer U 2000 AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407 94-98. (doi:10.1038/35024095)
2. AbdAlla S, Lother H, el Massiery A & Quitterer U 2001 Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nature Medicine 7 1003-1009. (doi:10.1038/nm0901-1003)
3. AbdAlla S, Lother H, el Missiry A, Sergeev P, Langer A, el Faramawy Y & Quitterer U 2009 Dominant negative AT2 receptor oligomers induce G-protein arrest and symptoms of neurodegeneration. Journal of Biological Chemistry 284 6566-6574. (doi:10.1074/jbc.M808277200)
4. Ahuja S & Smith SO 2009 Multiple switches in G protein-coupled receptor activation. Trends in Pharmacological Sciences 30 494-502.
5. Albizu L, Balestre MN, Breton C, Pin JP, Manning M, Mouillac B, Barberis C & Durroux T 2006 Probing the existence of G proteincoupled receptor dimers by positive and negative ligand-dependent cooperative binding. Molecular Pharmacology 70 1783-1791. (doi:10.1124/mol.106.025684)
6. Albizu L, Cottet M, Kralikova M, Stoev S, Seyer R, Brabet I, Roux T, Bazin H, Bourrier E, Lamarque L, et al. 2010a Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nature Chemical Biology 6 587-594. (doi:10.1038/nchembio.396)
7. Albizu L, Moreno JL, Gonzalez-Maeso J & Sealfon SC 2010b Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics. CNS & Neurological Disorders-Drug Targets 9 636-650. (doi:10.2174/187152710793361586)
8. Allen MD, Neumann S & Gershengorn MC 2011 Occupancy of both sites on the thyrotropin (TSH) receptor dimer is necessary for phosphoinositide signaling. FASEB Journal 25 3687-3694. (doi:10.1096/fj.11-188961)
9. Ardura JA & Friedman PA 2011 Regulation of G protein-coupled receptor function by Na+/H+ exchange regulatory factors. Pharmacological Reviews 63 882-900. (doi:10.1124/pr.110.004176)
10. Argiolas A 1992 Oxytocin stimulation of penile erection. Pharmacology, site, and mechanism of action. Annals of the New York Academy of Sciences 652 194-203. (doi:10.1111/j.1749-6632.1992.tb34355.x)
11. Bakker RA, Dees G, Carrillo JJ, Booth RG, Lopez-Gimenez JF, Milligan G, Strange PG & Leurs R 2004 Domain swapping in the human histamine H1 receptor. Journal of Pharmacology and Experimental Therapeutics 311 131-138. (doi:10.1124/jpet.104.067041)
12. Barsh GS, Farooqi IS & O'Rahilly S 2000 Genetics of body-weight regulation. Nature 404 644-651.
13. Beaulieu JM & Gainetdinov RR 2011 The physiology, signaling, and pharmacology of dopamine receptors. Pharmacological Reviews 63 182-217. (doi:10.1124/pr.110.002642)
14. Beaumont KA, Newton RA, Smit DJ, Leonard JH, Stow JL & Sturm RA 2005 Altered cell surface expression of human MC1R variant receptor alleles associated with red hair and skin cancer risk. Human Molecular Genetics 14 2145-2154. (doi:10.1093/hmg/ddi219)
15. Benkirane M, Jin DY, Chun RF, Koup RA & Jeang KT 1997 Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. Journal of Biological Chemistry 272 30603-30606. (doi:10.1074/jbc.272.49.30603)
16. Benleulmi-Chaachoua A, Chen L, Sokolina K, Wong V, Jurisica I, Emerit MB, Darmon M, Espin A, Stagljar I, Tafelmeyer P, et al. 2016 Protein interactome mining defines melatonin MT1 receptors as integral component of presynaptic protein complexes of neurons. Journal of Pineal Research 60 95-108. (doi:10.1111/jpi.12294)
17. Bianco AC, Anderson G, Forrest D, Galton VA, Gereben B, Kim BW, Kopp PA, Liao XH, Obregon MJ, Peeters RP, et al. 2014 American Thyroid Association Guide to investigating thyroid hormone economy and action in rodent and cell models. Thyroid 24 88-168. (doi:10.1089/thy.2013.0109)
18. Biebermann H, Krude H, Elsner A, Chubanov V, Gudermann T & Gruters A 2003 Autosomal-dominant mode of inheritance of a melanocortin-4 receptor mutation in a patient with severe earlyonset obesity is due to a dominant-negative effect caused by receptor dimerization. Diabetes 52 2984-2988. (doi:10.2337/ diabetes.52.12.2984)
19. Biebermann H, Kuhnen P, Kleinau G & Krude H 2012a The neuroendocrine circuitry controlled by POMC, MSH, and AGRP. Handbook of Experimental Pharmacology 209 47-75.
20. Biebermann H, Winkler F, Handke D, Teichmann A, Gerling B, Cameron F, Eichhorst J, Gruters A, Wiesner B, Kuhnen P, et al. 2012b New pathogenic thyrotropin receptor mutations decipher differentiated activity switching at a conserved helix 6 motif of family A GPCR. Journal of Clinical Endocrinology & Metabolism 97 E228-E232. (doi:10.1210/jc.2011-2106)
21. Bilek R 2000 TRH-like peptides in prostate gland and other tissues. Physiological Research 49 (Supplement 1) S19-S26.
22. Bonomi M & Persani L 2013 Modern methods to investigate the oligomerization of glycoprotein hormone receptors (TSHR, LHR, FSHR). Methods in Enzymology 521 367-383. (doi:10.1016/B978-0-12-391862-8.00020-X)
23. Bonomi M, Libri DV, Guizzardi F, Guarducci E, Maiolo E, Pignatti E, Asci R, Persani L, Idiopathic Central Hypogonadism Study Group of the Italian Societies of Endocrinology, Pediatric Endocrinology and Diabetes, et al. 2012 New understandings of the genetic basis of isolated idiopathic central hypogonadism. Asian Journal of Andrology 14 49-56. (doi:10.1038/aja.2011.68)
24. Borroto-Escuela DO, Brito I, Romero-Fernandez W, Di Palma M, Oflijan J, Skieterska K, Duchou J, Van Craenenbroeck K, Suarez-Boomgaard D, Rivera A, et al. 2014 The G protein-coupled receptor heterodimer network (GPCR-HetNet) and its hub components. International Journal of Molecular Sciences 15 8570-8590. (doi:10.3390/ ijms15058570)
25. Bouvier M 2001 Oligomerization of G-protein-coupled transmitter receptors. Nature Reviews Neuroscience 2 274-286. (doi:10.1038/ 35067575)
26. Brezillon S, Detheux M, Parmentier M, Hokfelt T & Hurd YL 2001 Distribution of an orphan G-protein coupled receptor (JP05) mRNA in the human brain. Brain Research 921 21-30. (doi:10.1016/S0006-8993(01)03068-2)
27. Brothers SP, Cornea A, Janovick JA & Conn PM 2004 Human loss-offunction gonadotropin-releasing hormone receptor mutants retain wild-type receptors in the endoplasmic reticulum: molecular basis of the dominant-negative effect. Molecular Endocrinology 18 1787-1797. (doi:10.1210/me.2004-0091)
28. Calebiro D, de Filippis T, Lucchi S, Covino C, Panigone S, Beck-Peccoz P, Dunlap D & Persani L 2005 Intracellular entrapment of wild-type TSH receptor by oligomerization with mutants linked to dominant TSH resistance. Human Molecular Genetics 14 2991-3002. (doi:10.1093/hmg/ddi329)
29. Calebiro D, Rieken F, Wagner J, Sungkaworn T, Zabel U, Borzi A, Cocucci E, Zurn A & Lohse MJ 2013 Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. PNAS 110 743-748. (doi:10.1073/pnas.1205798110)
30. Cao J, O'Donnell D, Vu H, Payza K, Pou C, Godbout C, Jakob A, Pelletier M, Lembo P, Ahmad S, et al. 1998 Cloning and characterization of a cDNA encoding a novel subtype of rat thyrotropin-releasing hormone receptor. Journal of Biological Chemistry 273 32281-32287. (doi:10.1074/jbc.273.48.32281)
31. Carlsson J, Coleman RG, Setola V, Irwin JJ, Fan H, Schlessinger A, Sali A, Roth BL & Shoichet BK 2011 Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nature Chemical Biology 7 769-778. (doi:10.1038/nchembio.662)
32. Carrillo JJ, Lopez-Gimenez JF & Milligan G 2004 Multiple interactions between transmembrane helices generate the oligomeric alpha1badrenoceptor. Molecular Pharmacology 66 1123-1137. (doi:10.1124/ mol.104.001586)
33. Chaly AL, Srisai D, Gardner EE & Sebag JA 2016 The Melanocortin receptor accessory protein 2 promotes food intake through inhibition of the prokineticin receptor-1. Elife 5 pii: e12397.
34. Chen J, Kuei C, Sutton S, Wilson S, Yu J, Kamme F, Mazur C, Lovenberg T & Liu C 2005 Identification and pharmacological characterization of prokineticin 2 beta as a selective ligand for prokineticin receptor 1. Molecular Pharmacology 67 2070-2076. (doi:10.1124/mol.105.011619)
35. Ciruela F, Vilardaga JP & Fernandez-Duenas V 2010 Lighting up multiprotein complexes: lessons from GPCR oligomerization. Trends in Biotechnology 28 407-415. (doi:10.1016/j.tibtech.2010.05.002)
36. Ciruela F, Jacobson KA & Fernandez-Duenas V 2014 Portraying G protein-coupled receptors with fluorescent ligands. ACS Chemical Biology 9 1918-1928. (doi:10.1021/cb5004042)
37. Cohen BD, Nechamen CA & Dias JA 2004 Human follitropin receptor (FSHR) interacts with the adapter protein 14-3-3tau. Molecular and Cellular Endocrinology 220 1-7. (doi:10.1016/j.mce.2004.04.012)
38. Cone RD 2005 Anatomy and regulation of the central melanocortin system. Nature Neuroscience 8 571-578. (doi:10.1038/nn1455)
39. Conn PM, Rogers DC & McNeil R 1982a Potency enhancement of a GnRH agonist: GnRH-receptor microaggregation stimulates gonadotropin release. Endocrinology 111 335-337. (doi:10.1210/endo-111-1-335)
40. Conn PM, Rogers DC, Stewart JM, Neidel J & Sheffield T 1982b Conversion of a gonadotropin releasing hormone antagonist to an agonist. Nature 296 653-655. (doi:10.1038/296653a0)
41. Cooray SN & Clark AJ 2011 Melanocortin receptors and their accessory proteins. Molecular and Cellular Endocrinology 331 215-221. (doi:10.1016/j.mce.2010.07.015)
42. Cornea A, Janovick JA, Maya-Nunez G & Conn PM 2001 Gonadotropinreleasing hormone receptor microaggregation. Rate monitored by fluorescence resonance energy transfer. Journal of Biological Chemistry 276 2153-2158. (doi:10.1074/jbc.M007850200)
43. Davies T, Marians R & Latif R 2002 The TSH receptor reveals itself. Journal of Clinical Investigation 110 161-164. (doi:10.1172/ JCI0216234)
44. De Moerlooze L, Williamson J, Liners F, Perret J & Parmentier M 2000 Cloning and chromosomal mapping of the mouse and human genes encoding the orphan glucocorticoid-induced receptor (GPR83). Cytogenetics and Cell Genetics 90 146-150. (doi:10.1159/000015650)
45. Decaillot FM, Rozenfeld R, Gupta A & Devi LA 2008 Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4. PNAS 105 16045-16050. (doi:10.1073/pnas.0804106105)
46. Dehvari N, Hutchinson DS, Nevzorova J, Dallner OS, Sato M, Kocan M, Merlin J, Evans BA, Summers RJ & Bengtsson T 2012 beta(2)-Adrenoceptors increase translocation of GLUT4 via GPCR kinase sites in the receptor C-terminal tail. British Journal of Pharmacology 165 1442-1456. (doi:10.1111/j.1476-5381.2011.01647.x)
47. Deupi X & Standfuss J 2011 Structural insights into agonist-induced activation of G-protein-coupled receptors. Current Opinion in Structural Biology 21 541-551. (doi:10.1016/j.sbi.2011.06.002)
48. Dinger MC, Bader JE, Kobor AD, Kretzschmar AK & Beck-Sickinger AG 2003 Homodimerization of neuropeptide y receptors investigated by fluorescence resonance energy transfer in living cells. Journal of Biological Chemistry 278 10562-10571. (doi:10.1074/jbc. M205747200)
49. Dinter J, Khajavi N, Muhlhaus J, Wienchol CL, Coster M, Hermsdorf T, Staubert C, Kohrle J, Schoneberg T, Kleinau G, et al. 2015a The multitarget ligand 3-iodothyronamine modulates beta-adrenergic receptor 2 signaling. European Thyroid Journal 4 21-29.
50. Dinter J, Muhlhaus J, Jacobi SF, Wienchol CL, Coster M, Meister J, Hoefig CS, Muller A, Kohrle J, Gruters A, et al. 2015b 3-iodothyronamine differentially modulates alpha-2A-adrenergic receptor-mediated signaling. Journal of Molecular Endocrinology 54 205-216.
51. Dode C, Teixeira L, Levilliers J, Fouveaut C, Bouchard P, Kottler ML, Lespinasse J, Lienhardt-Roussie A, Mathieu M, Moerman A, et al. 2006 Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genetics 2 e175.
52. Dorsam RT & Gutkind JS 2007 G-protein-coupled receptors and cancer. Nature Reviews Cancer 7 79-94. (doi:10.1038/nrc2069)
53. Doupnik CA 2008 GPCR-Kir channel signaling complexes: defining rules of engagement. Journal of Receptors and Signal Transduction Research 28 83-91. (doi:10.1080/10799890801941970)
54. Dunn HA & Ferguson SS 2015 PDZ Protein regulation of G proteincoupled receptor trafficking and signaling pathways. Molecular Pharmacology 88 624-639. (doi:10.1124/mol.115.098509)
55. Durroux T 2005 Principles: a model for the allosteric interactions between ligand binding sites within a dimeric GPCR. Trends in Pharmacological Sciences 26 376-384. (doi:10.1016/j. tips.2005.05.006)
56. Ebner NC, Maura GM, Macdonald K, Westberg L & Fischer H 2013 Oxytocin and socioemotional aging: Current knowledge and future trends. Frontiers in Human Neuroscience 7 487.
57. Ellis J, Pediani JD, Canals M, Milasta S & Milligan G 2006 Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and-independent coordinated alterations of receptor localization and function. Journal of Biological Chemistry 281 38812-38824. (doi:10.1074/jbc.M602494200)
58. Fanelli F 2007 Dimerization of the lutropin receptor: insights from computational modeling. Molecular and Cellular Endocrinology 260-262 59-64.
59. Farooqi S 2014 Genetic strategies to understand physiological pathways regulating body weight. Mammalian Genome 25 377-383. (doi:10.1007/s00335-014-9541-z)
60. Feng X, Zhang M, Guan R & Segaloff DL 2013 Heterodimerization between the lutropin and follitropin receptors is associated with an attenuation of hormone-dependent signaling. Endocrinology 154 3925-3930. (doi:10.1210/en.2013-1407)
61. Ferre S 2015 The GPCR heterotetramer: challenging classical pharmacology. Trends in Pharmacological Sciences 36 145-152. (doi:10.1016/j.tips.2015.01.002)
62. Ferre S & Franco R 2010 Oligomerization of G-protein-coupled receptors: a reality. Current Opinion in Pharmacology 10 1-5. (doi:10.1016/j. coph.2009.11.002)
63. Frederick AL, Yano H, Trifilieff P, Vishwasrao HD, Biezonski D, Meszaros J, Urizar E, Sibley DR, Kellendonk C, Sonntag KC, et al. 2015 Evidence against dopamine D1/D2 receptor heteromers. Molecular Psychiatry 20 1373-1385. (doi:10.1038/mp.2014.166)
64. Fredriksson R & Schioth HB 2005 The repertoire of G-protein-coupled receptors in fully sequenced genomes. Molecular Pharmacology 67 1414-1425. (doi:10.1124/mol.104.009001)
65. Fredriksson R, Lagerstrom MC, Lundin LG & Schioth HB 2003 The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Molecular Pharmacology 63 1256-1272.
66. Fuxe K, Borroto-Escuela DO, Marcellino D, Romero-Fernandez W, Frankowska M, Guidolin D, Filip M, Ferraro L, Woods AS, Tarakanov A, et al. 2012 GPCR heteromers and their allosteric receptor-receptor interactions. Current Medicinal Chemistry 19 356-363. (doi:10.2174/092986712803414259)
67. Galandrin S, Oligny-Longpre G & Bouvier M 2007 The evasive nature of drug efficacy: implications for drug discovery. Trends in Pharmacological Sciences 28 423-430. (doi:10.1016/j.tips.2007.06.005)
68. Garcia-Jimenez C & Santisteban P 2007 TSH signalling and cancer. Arquivos Brasileiros de Endocrinologia & Metabologia 51 654-671.
69. Garfield AS, Li C, Madara JC, Shah BP, Webber E, Steger JS, Campbell JN, Gavrilova O, Lee CE, Olson DP, et al. 2015 A neural basis for melanocortin-4 receptor-regulated appetite. Nature Neuroscience 18 863-871. (doi:10.1038/nn.4011)
70. Garland SL 2013 Are GPCRs still a source of new targets? Journal of Biomolecular Screening 18 947-966. (doi:10.1177/1087057113498418)
71. George SR, Lee SP, Varghese G, Zeman PR, Seeman P, Ng GY & O'Dowd BF 1998 A transmembrane domain-derived peptide inhibits D1 dopamine receptor function without affecting receptor oligomerization. Journal of Biological Chemistry 273 30244-30248. (doi:10.1074/jbc.273.46.30244)
72. George SR, O'Dowd BF & Lee SP 2002 G-protein-coupled receptor oligomerization and its potential for drug discovery. Nature Reviews Drug Discovery 1 808-820. (doi:10.1038/nrd913)
73. Gimpl G & Fahrenholz F 2001 The oxytocin receptor system: structure, function, and regulation. Physiological Reviews 81 629-683.
74. Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V & Devi LA 2000 Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. Journal of Neuroscience 20 RC110.
75. Gomes I, Fujita W, Chandrakala MV & Devi LA 2013 Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse. Progress in Molecular Biology and Translational Science 117 207-265. (doi:10.1016/B978-0-12-386931-9.00009-X)
76. Gomes I, Gupta A, Bushlin I & Devi LA 2014 Antibodies to probe endogenous G protein-coupled receptor heteromer expression, regulation, and function. Frontiers in Pharmacology 5 268.
77. Gomes I, Ayoub MA, Fujita W, Jaeger WC, Pfleger KD & Devi LA 2016 G protein-coupled receptor heteromers. Annual Review of Pharmacology and Toxicology 56 403-425. (doi:10.1146/annurevpharmtox-011613-135952)
78. Gonzalez S, Moreno-Delgado D, Moreno E, Perez-Capote K, Franco R, Mallol J, Cortes A, Casado V, Lluis C, Ortiz J, et al. 2012 Circadianrelated heteromerization of adrenergic and dopamine D(4) receptors modulates melatonin synthesis and release in the pineal gland. PLoS Biology 10 e1001347.
79. Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF, Zhou M, Okawa Y, Callado LF, Milligan G, et al. 2008 Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452 93-97. (doi:10.1038/nature06612)
80. Gorinski N, Kowalsman N, Renner U, Wirth A, Reinartz MT, Seifert R, Zeug A, Ponimaskin E & Niv MY 2012 Computational and experimental analysis of the transmembrane domain 4/5 dimerization interface of the serotonin 5-HT(1A) receptor. Molecular Pharmacology 82 448-463. (doi:10.1124/mol.112.079137)
81. Grosse R, Schoneberg T, Schultz G & Gudermann T 1997 Inhibition of gonadotropin-releasing hormone receptor signaling by expression of a splice variant of the human receptor. Molecular Endocrinology 11 1305-1318. (doi:10.1210/mend.11.9.9966)
82. Guo W, Shi L & Javitch JA 2003 The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer. Journal of Biological Chemistry 278 4385-4388. (doi:10.1074/jbc.C200679200)
83. Guo W, Shi L, Filizola M, Weinstein H & Javitch JA 2005 Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. PNAS 102 17495-17500. (doi:10.1073/pnas.0508950102)
84. Guo W, Urizar E, Kralikova M, Mobarec JC, Shi L, Filizola M & Javitch JA 2008 Dopamine D2 receptors form higher order oligomers at physiological expression levels. EMBO Journal 27 2293-2304. (doi:10.1038/emboj.2008.153)
85. Hague C, Lee SE, Chen Z, Prinster SC, Hall RA & Minneman KP 2006 Heterodimers of alpha1B-and alpha1D-adrenergic receptors form a single functional entity. Molecular Pharmacology 69 45-55.
86. Hall RA, Premont RT, Chow CW, Blitzer JT, Pitcher JA, Claing A, Stoffel RH, Barak LS, Shenolikar S, Weinman EJ, et al. 1998 The beta2-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange. Nature 392 626-630. (doi:10.1038/33458)
87. Hanson MA & Stevens RC 2009 Discovery of new GPCR biology: one receptor structure at a time. Structure 17 8-14. (doi:10.1016/j. str.2008.12.003)
88. Hanyaloglu AC, Seeber RM, Kohout TA, Lefkowitz RJ & Eidne KA 2002 Homo-and hetero-oligomerization of thyrotropin-releasing hormone (TRH) receptor subtypes. Differential regulation of beta-arrestins 1 and 2. Journal of Biological Chemistry 277 50422-50430. (doi:10.1074/ jbc.M209340200)
89. Harikumar KG, Morfis MM, Sexton PM & Miller LJ 2008 Pattern of intra-family hetero-oligomerization involving the G-protein-coupled secretin receptor. Journal of Molecular Neuroscience 36 279-285. (doi:10.1007/s12031-008-9060-z)
90. Harmeier A, Obermueller S, Meyer CA, Revel FG, Buchy D, Chaboz S, Dernick G, Wettstein JG, Iglesias A, Rolink A, et al. 2015 Trace amine-associated receptor 1 activation silences GSK3beta signaling of TAAR1 and D2R heteromers. European Neuropsychopharmacology 25 2049-2061. (doi:10.1016/j.euroneuro.2015.08.011)
91. Harrigan MT, Baughman G, Campbell NF & Bourgeois S 1989 Isolation and characterization of glucocorticoid-and cyclic AMP-induced genes in T lymphocytes. Molecular and Cellular Biology 9 3438-3446. (doi:10.1128/MCB.9.8.3438)
92. Harrigan MT, Campbell NF & Bourgeois S 1991 Identification of a gene induced by glucocorticoids in murine T-cells: a potential G proteincoupled receptor. Molecular Endocrinology 5 1331-1338. (doi:10.1210/ mend-5-9-1331)
93. Hay DL, Poyner DR & Sexton PM 2006 GPCR modulation by RAMPs. Pharmacology & Therapeutics 109 173-197.
94. Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C & Bouvier M 1996 A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. Journal of Biological Chemistry 271 16384-16392. (doi:10.1074/jbc.271.27.16384)
95. Heng BC, Aubel D & Fussenegger M 2013 An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases. Biotechnology Advances 31 1676-1694. (doi:10.1016/j.biotechadv.2013.08.017)
96. Hern JA, Baig AH, Mashanov GI, Birdsall B, Corrie JE, Lazareno S, Molloy JE & Birdsall NJ 2010 Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. PNAS 107 2693-2698. (doi:10.1073/pnas.0907915107)
97. Hernanz-Falcon P, Rodriguez-Frade JM, Serrano A, Juan D, del Sol A, Soriano SF, Roncal F, Gomez L, Valencia A, Martinez AC, et al. 2004 Identification of amino acid residues crucial for chemokine receptor dimerization. Nature Immunology 5 216-223. (doi:10.1038/ni1027)
98. Herrick-Davis K, Grinde E, Cowan A & Mazurkiewicz JE 2013 Fluorescence correlation spectroscopy analysis of serotonin, adrenergic, muscarinic, and dopamine receptor dimerization: the oligomer number puzzle. Molecular Pharmacology 84 630-642. (doi:10.1124/mol.113.087072)
99. Heuer H, Schafer MK & Bauer K 1999 Thyrotropin-releasing hormone (TRH), a signal peptide of the central nervous system. Acta Medica Austriaca 26 119-122.
100. Hink MA & Postma M 2013 Monitoring receptor oligomerization by line-scan fluorescence cross-correlation spectroscopy. Methods in Cell Biology 117 197-212. (doi:10.1016/B978-0-12-408143-7.00011-6)
101. Ho MK, Su Y, Yeung WW & Wong YH 2009 Regulation of transcription factors by heterotrimeric G proteins. Current Molecular Pharmacology 2 19-31. (doi:10.2174/1874467210902010019)
102. Hofmann KP, Scheerer P, Hildebrand PW, Choe HW, Park JH, Heck M & Ernst OP 2009 A G protein-coupled receptor at work: the rhodopsin model. Trends in Biochemical Sciences 34 540-552. (doi:10.1016/j. tibs.2009.07.005)
103. Hopkins AL & Groom CR 2002 The druggable genome. Nature Reviews Drug Discovery 1 727-730. (doi:10.1038/nrd892)
104. Hu J, Hu K, Liu T, Stern MK, Mistry R, Challiss RA, Costanzi S & Wess J 2013 Novel structural and functional insights into M3 muscarinic receptor dimer/oligomer formation. Journal of Biological Chemistry 288 34777-34790. (doi:10.1074/jbc.M113.503714)
105. Hutchings CJ, Koglin M & Marshall FH 2010 Therapeutic antibodies directed at G protein-coupled receptors. mAbs 2 594-606. (doi:10.4161/mabs.2.6.13420)
106. Ibrahim S, Tetruashvily M, Frey AJ, Wilson SJ, Stitham J, Hwa J & Smyth EM 2010 Dominant negative actions of human prostacyclin receptor variant through dimerization: implications for cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 30 1802-1809. (doi:10.1161/ATVBAHA.110.208900)
107. Jackson DS, Ramachandrappa S, Clark AJ & Chan LF 2015 Melanocortin receptor accessory proteins in adrenal disease and obesity. Frontiers in Neuroscience 9 213.
108. Ji I, Lee C, Song Y, Conn PM & Ji TH 2002 Cis-and trans-activation of hormone receptors: the LH receptor. Molecular Endocrinology 16 1299-1308. (doi:10.1210/mend.16.6.0852)
109. Ji I, Lee C, Jeoung M, Koo Y, Sievert GA & Ji TH 2004 Trans-activation of mutant follicle-stimulating hormone receptors selectively generates only one of two hormone signals. Molecular Endocrinology 18 968-978. (doi:10.1210/me.2003-0443)
110. Jiang H, Betancourt L & Smith RG 2006 Ghrelin amplifies dopamine signaling by cross talk involving formation of growth hormone secretagogue receptor/dopamine receptor subtype 1 heterodimers. Molecular Endocrinology 20 1772-1785. (doi:10.1210/me.2005-0084)
111. Jonas KC, Fanelli F, Huhtaniemi IT & Hanyaloglu AC 2015 Single molecule analysis of functionally asymmetric G protein-coupled receptor (GPCR) oligomers reveals diverse spatial and structural assemblies. Journal of Biological Chemistry 290 3875-3892. (doi:10.1074/jbc.M114.622498)
112. Juhasz JR, Hasbi A, Rashid AJ, So CH, George SR & O'Dowd BF 2008 Mu-opioid receptor heterooligomer formation with the dopamine D1 receptor as directly visualized in living cells. European Journal of Pharmacology 581 235-243. (doi:10.1016/j.ejphar.2007.11.060)
113. Kaczor AA & Selent J 2011 Oligomerization of G protein-coupled receptors: biochemical and biophysical methods. Current Medicinal Chemistry 18 4606-4634. (doi:10.2174/092986711797379285)
114. Kasahara Y, Sato K, Takayanagi Y, Mizukami H, Ozawa K, Hidema S, So KH, Kawada T, Inoue N, Ikeda I, et al. 2013 Oxytocin receptor in the hypothalamus is sufficient to rescue normal thermoregulatory function in male oxytocin receptor knockout mice. Endocrinology 154 4305-4315. (doi:10.1210/en.2012-2206)
115. Kasai RS, Suzuki KG, Prossnitz ER, Koyama-Honda I, Nakada C, Fujiwara TK & Kusumi A 2011 Full characterization of GPCR monomer-dimer dynamic equilibrium by single molecule imaging. Journal of Cell Biology 192 463-480. (doi:10.1083/jcb.201009128)
116. Kern A, Albarran-Zeckler R, Walsh HE & Smith RG 2012 Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism. Neuron 73 317-332. (doi:10.1016/j.neuron.2011.10.038)
117. Kern A, Mavrikaki M, Ullrich C, Albarran-Zeckler R, Brantley AF & Smith RG 2015 Hippocampal dopamine/DRD1 signaling dependent on the ghrelin receptor. Cell 163 1176-1190. (doi:10.1016/j. cell.2015.10.062)
118. Khelashvili G, Dorff K, Shan J, Camacho-Artacho M, Skrabanek L, Vroling B, Bouvier M, Devi LA, George SR, Javitch JA, et al. 2010 GPCR-OKB: the G protein coupled receptor oligomer knowledge base. Bioinformatics 26 1804-1805. (doi:10.1093/bioinformatics/btq264)
119. Kilpatrick LE, Humphrys LJ & Holliday ND 2015 A G protein-coupled receptor dimer imaging assay reveals selectively modified pharmacology of neuropeptide Y Y1/Y5 receptor heterodimers. Molecular Pharmacology 87 718-732. (doi:10.1124/mol.114.095356)
120. Kleinau G & Krause G 2009 Thyrotropin and homologous glycoprotein hormone receptors: structural and functional aspects of extracellular signaling mechanisms. Endocrine Reviews 30 133-151. (doi:10.1210/ er.2008-0044)
121. Kleinau G, Pratzka J, Nurnberg D, Gruters A, Fuhrer-Sakel D, Krude H, Kohrle J, Schoneberg T & Biebermann H 2011 Differential modulation of Beta-adrenergic receptor signaling by trace amineassociated receptor 1 agonists. PLoS ONE 6 e27073.
122. Kleinau G, Neumann S, Gruters A, Krude H & Biebermann H 2013 Novel insights on thyroid-stimulating hormone receptor signal transduction. Endocrine Reviews 34 691-724. (doi:10.1210/er.2012-1072)
123. Kobilka BK & Deupi X 2007 Conformational complexity of G-proteincoupled receptors. Trends in Pharmacological Sciences 28 397-406. (doi:10.1016/j.tips.2007.06.003)
124. Kobilka B & Schertler GF 2008 New G-protein-coupled receptor crystal structures: insights and limitations. Trends in Pharmacological Sciences 29 79-83. (doi:10.1016/j.tips.2007.11.009)
125. Kontoyianni M & Liu Z 2012 Structure-based design in the GPCR target space. Current Medicinal Chemistry 19 544-556. (doi:10.2174/0929867 12798918824)
126. Kopanchuk S, Veiksina S, Mutulis F, Mutule I, Yahorava S, Mandrika I, Petrovska R, Rinken A & Wikberg JE 2006 Kinetic evidence for tandemly arranged ligand binding sites in melanocortin 4 receptor complexes. Neurochemistry International 49 533-542. (doi:10.1016/j. neuint.2006.04.006)
127. Kristiansen K 2004 Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacology & Therapeutics 103 21-80.
128. Kroeger KM, Hanyaloglu AC, Seeber RM, Miles LE & Eidne KA 2001 Constitutive and agonist-dependent homo-oligomerization of the thyrotropin-releasing hormone receptor. Detection in living cells using bioluminescence resonance energy transfer. Journal of Biological Chemistry 276 12736-12743. (doi:10.1074/jbc.M011311200)
129. Kurada P & O'Tousa JE 1995 Retinal degeneration caused by dominant rhodopsin mutations in Drosophila. Neuron 14 571-579. (doi:10.1016/0896-6273(95)90313-5)
130. Laffray S, Bouali-Benazzouz R, Papon MA, Favereaux A, Jiang Y, Holm T, Spriet C, Desbarats P, Fossat P, Le Feuvre Y, et al. 2012 Impairment of GABAB receptor dimer by endogenous 14-3-3zeta in chronic pain conditions. EMBO Journal 31 3239-3251. (doi:10.1038/ emboj.2012.161)
131. Lambert NA 2010 GPCR dimers fall apart. Science Signaling 3 pe12.
132. Latif R, Graves P & Davies TF 2001 Oligomerization of the human thyrotropin receptor: fluorescent protein-tagged hTSHR reveals posttranslational complexes. Journal of Biological Chemistry 276 45217-45224. (doi:10.1074/jbc.M103727200)
133. Law CJ, Maloney PC & Wang DN 2008 Ins and outs of major facilitator superfamily antiporters. Annual Review of Microbiology 62 289-305. (doi:10.1146/annurev.micro.61.080706.093329)
134. Levoye A, Dam J, Ayoub MA, Guillaume JL, Couturier C, Delagrange P & Jockers R 2006a The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO Journal 25 3012-3023.
135. Levoye A, Dam J, Ayoub MA, Guillaume JL & Jockers R 2006b Do orphan G-protein-coupled receptors have ligand-independent functions? New insights from receptor heterodimers. EMBO Reports 7 1094-1098.
136. Li X & Ma S 2013 Recent developments in the discovery of novel antipsychotic agents modualating dopamine and serotonin receptors. Current Drug Targets 14 899-918. (doi:10.2174/1389450111 3149990007)
137. Li X, Staszewski L, Xu H, Durick K, Zoller M & Adler E 2002 Human receptors for sweet and umami taste. PNAS 99 4692-4696. (doi:10.1073/pnas.072090199)
138. Libri DV, Kleinau G, Vezzoli V, Busnelli M, Guizzardi F, Sinisi AA, Pincelli AI, Mancini A, Russo G, Beck-Peccoz P, et al. 2014 Germline prokineticin receptor 2 (PROKR2) variants associated with central hypogonadism cause differental modulation of distinct intracellular pathways. Journal of Clinical Endocrinology & Metabolism 99 E458-E463.
139. Limbird LE 2004 The receptor concept: a continuing evolution. Molecular Interventions 4 326-336. (doi:10.1124/mi.4.6.6)
140. Lodowski DT, Angel TE & Palczewski K 2009 Comparative analysis of GPCR crystal structures. Photochemistry and Photobiology 85 425-430. (doi:10.1111/j.1751-1097.2008.00516.x)
141. Lohse MJ 2010 Dimerization in GPCR mobility and signaling. Current Opinion in Pharmacology 10 53-58. (doi:10.1016/j.coph.2009.10.007)
142. Lohse MJ, Nuber S & Hoffmann C 2012 Fluorescence/bioluminescence resonance energy transfer techniques to study G-protein-coupled receptor activation and signaling. Pharmacological Reviews 64 299-336. (doi:10.1124/pr.110.004309)
143. Magalhaes AC, Holmes KD, Dale LB, Comps-Agrar L, Lee D, Yadav PN, Drysdale L, Poulter MO, Roth BL, Pin JP, et al. 2010 CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nature Neuroscience 13 622-629. (doi:10.1038/nn.2529)
144. Maldonado-Perez D, Evans J, Denison F, Millar RP & Jabbour HN 2007 Potential roles of the prokineticins in reproduction. Trends Endocrinol Metab 18 66-72. (doi:10.1016/j.tem.2006.12.002)
145. Malik AI, Zai CC, Abu Z, Nowrouzi B & Beitchman JH 2012 The role of oxytocin and oxytocin receptor gene variants in childhood-onset aggression. Genes, Brain and Behavior 11 545-551. (doi:10.1111/j.1601-183X.2012.00776.x)
146. Mancia F, Assur Z, Herman AG, Siegel R & Hendrickson WA 2008 Ligand sensitivity in dimeric associations of the serotonin 5HT2c receptor. EMBO Reports 9 363-369. (doi:10.1038/embor.2008.27)
147. Mandrika I, Petrovska R & Wikberg J 2005 Melanocortin receptors form constitutive homo-and heterodimers. Biochemical and Biophysical Research Communications 326 349-354. (doi:10.1016/j. bbrc.2004.11.036)
148. Marsango S, Bonaccorsi di Patti MC, Barra D & Miele R 2011 Evidence that prokineticin receptor 2 exists as a dimer in vivo. Cellular and Molecular Life Sciences 68 2919-2929.
149. Mason JS, Bortolato A, Congreve M & Marshall FH 2012 New insights from structural biology into the druggability of G protein-coupled receptors. Trends in Pharmacological Sciences 33 249-260. (doi:10.1016/j.tips.2012.02.005)
150. Matsumoto S, Yamazaki C, Masumoto KH, Nagano M, Naito M, Soga T, Hiyama H, Matsumoto M, Takasaki J, Kamohara M, et al. 2006 Abnormal development of the olfactory bulb and reproductive system in mice lacking prokineticin receptor PKR2. PNAS 103 4140-4145. (doi:10.1073/pnas.0508881103)
151. Maurice P, Guillaume JL, Benleulmi-Chaachoua A, Daulat AM, Kamal M & Jockers R 2011a GPCR-interacting proteins, major players of GPCR function. Advances in Pharmacology 62 349-380.
152. Maurice P, Kamal M & Jockers R 2011b Asymmetry of GPCR oligomers supports their functional relevance. Trends in Pharmacological Sciences 32 514-520.
153. Mazurkiewicz JE, Herrick-Davis K, Barroso M, Ulloa-Aguirre A, Lindau-Shepard B, Thomas RM & Dias JA 2015 Single-molecule analyses of fully functional fluorescent protein-tagged follitropin receptor reveal homodimerization and specific heterodimerization with lutropin receptor. Biology of Reproduction 92 100. (doi:10.1095/ biolreprod.114.125781)
154. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG & Foord SM 1998 RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393 333-339. (doi:10.1038/30666)
155. McMillin SM, Heusel M, Liu T, Costanzi S & Wess J 2011 Structural basis of M3 muscarinic receptor dimer/oligomer formation. Journal of Biological Chemistry 286 28584-28598. (doi:10.1074/jbc. M111.259788)
156. Metherell LA, Chapple JP, Cooray S, David A, Becker C, Ruschendorf F, Naville D, Begeot M, Khoo B, Nurnberg P, et al. 2005 Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nature Genetics 37 166-170.
157. Mohr K, Schmitz J, Schrage R, Trankle C & Holzgrabe U 2013 Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at g protein coupled receptors. Angewandte Chemie International Edition in English 52 508-516. (doi:10.1002/ anie.201205315)
158. Muller A, Kleinau G, Piechowski CL, Muller TD, Finan B, Pratzka J, Gruters A, Krude H, Tschop M & Biebermann H 2013a G-protein coupled receptor 83 (GPR83) signaling determined by constitutive and zinc(II)-induced activity. PLoS ONE 8 e53347.
159. Muller TD, Muller A, Yi CX, Habegger KM, Meyer CW, Gaylinn BD, Finan B, Heppner K, Trivedi C, Bielohuby M, et al. 2013b The orphan receptor Gpr83 regulates systemic energy metabolism via ghrelin-dependent and ghrelin-independent mechanisms. Nature Communications 4 1968.
160. Murat B, Devost D, Andres M, Mion J, Boulay V, Corbani M, Zingg HH & Guillon G 2012 V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH. Molecular Endocrinology 26 502-520. (doi:10.1210/me.2011-1202)
161. Navarro G, Carriba P, Gandia J, Ciruela F, Casado V, Cortes A, Mallol J, Canela EI, Lluis C & Franco R 2008 Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-proteincoupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. Scientific World Journal 8 1088-1097. (doi:10.1100/tsw.2008.136)
162. Negri L, Lattanzi R, Giannini E & Melchiorri P 2007 Bv8/Prokineticin proteins and their receptors. Life Sciences 81 1103-1116. (doi:10.1016/j.lfs.2007.08.011)
163. Ng HK & Chow BK 2015 Oligomerization of family B GPCRs: exploration in inter-family oligomer formation. Frontiers in Endocrinology 6 10.
164. Ng KL, Li JD, Cheng MY, Leslie FM, Lee AG & Zhou QY 2005 Dependence of olfactory bulb neurogenesis on prokineticin 2 signaling. Science 308 1923-1927. (doi:10.1126/science.1112103)
165. Ng SY, Lee LT & Chow BK 2012 Receptor oligomerization: from early evidence to current understanding in class B GPCRs. Frontiers in Endocrinology 3 175.
166. Nijmeijer S, Leurs R, Smit MJ & Vischer HF 2010 The Epstein-Barr virusencoded G protein-coupled receptor BILF1 hetero-oligomerizes with human CXCR4, scavenges Galphai proteins, and constitutively impairs CXCR4 functioning. Journal of Biological Chemistry 285 29632-29641. (doi:10.1074/jbc.M110.115618)
167. Nygaard R, Frimurer TM, Holst B, Rosenkilde MM & Schwartz TW 2009 Ligand binding and micro-switches in 7TM receptor structures. Trends in Pharmacological Sciences 30 249-259. (doi:10.1016/j.tips.2009.02.006)
168. O'Hayre M, Vazquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S & Gutkind JS 2013 The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nature Reviews Cancer 13 412-424. (doi:10.1038/nrc3521)
169. Oldham WM & Hamm HE 2008 Heterotrimeric G protein activation by G-protein-coupled receptors. Nature Reviews Molecular Cell Biology 9 60-71. (doi:10.1038/nrm2299)
170. Osuga Y, Hayashi M, Kudo M, Conti M, Kobilka B & Hsueh AJ 1997 Co-expression of defective luteinizing hormone receptor fragments partially reconstitutes ligand-induced signal generation. Journal of Biological Chemistry 272 25006-25012.
171. Oswal A & Yeo GS 2007 The leptin melanocortin pathway and the control of body weight: lessons from human and murine genetics. Obesity Reviews 8 293-306. (doi:10.1111/j.1467-789x.2007.00378.x)
172. Overton MC & Blumer KJ 2000 G-protein-coupled receptors function as oligomers in vivo. Current Biology 10 341-344. (doi:10.1016/S0960-9822(00)00386-9)
173. Park S, Jiang H, Zhang H & Smith RG 2012 Modification of ghrelin receptor signaling by somatostatin receptor-5 regulates insulin release. PNAS 109 19003-19008. (doi:10.1073/pnas.1209590109)
174. Pei L, Li S, Wang M, Diwan M, Anisman H, Fletcher PJ, Nobrega JN & Liu F 2010 Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects. Nature Medicine 16 1393-1395. (doi:10.1038/nm.2263)
175. Pellissier LP, Barthet G, Gaven F, Cassier E, Trinquet E, Pin JP, Marin P, Dumuis A, Bockaert J, Baneres JL, et al. 2011 G protein activation by serotonin type 4 receptor dimers: evidence that turning on two protomers is more efficient. Journal of Biological Chemistry 286 9985-9997. (doi:10.1074/jbc.M110.201939)
176. Perreault ML, Hasbi A, O'Dowd BF & George SR 2014 Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance. Neuropsychopharmacology 39 156-168. (doi:10.1038/npp.2013.148)
177. Persani L, Calebiro D & Bonomi M 2007 Technology insight: modern methods to monitor protein-protein interactions reveal functional TSH receptor oligomerization. Nature Clinical Practice Endocrinology & Metabolism 3 180-190.
178. Pfeiffer M, Koch T, Schroder H, Laugsch M, Hollt V & Schulz S 2002 Heterodimerization of somatostatin and opioid receptors crossmodulates phosphorylation, internalization, and desensitization. Journal of Biological Chemistry 277 19762-19772. (doi:10.1074/jbc.M110373200)
179. Piechowski CL, Rediger A, Lagemann C, Muhlhaus J, Muller A, Pratzka J, Tarnow P, Gruters A, Krude H, Kleinau G, et al. 2013 Inhibition of melanocortin-4 receptor dimerization by substitutions in intracellular loop 2. Journal of Molecular Endocrinology 51 109-118. (doi:10.1530/JME-13-0061)
180. Pin JP, Neubig R, Bouvier M, Devi L, Filizola M, Javitch JA, Lohse MJ, Milligan G, Palczewski K, Parmentier M, et al. 2007 International union of basic and clinical pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacological Reviews 59 5-13. (doi:10.1124/ pr.59.1.5)
181. Piscitelli CL, Kean J, de Graaf C & Deupi X 2015 A Molecular pharmacologist's guide to G protein-coupled receptor crystallography. Molecular Pharmacology 88 536-551. (doi:10.1124/mol.115.099663)
182. Prinster SC, Hague C & Hall RA 2005 Heterodimerization of g proteincoupled receptors: specificity and functional significance. Pharmacological Reviews 57 289-298. (doi:10.1124/pr.57.3.1)
183. Raivio T, Avbelj M, McCabe MJ, Romero CJ, Dwyer AA, Tommiska J, Sykiotis GP, Gregory LC, Diaczok D, Tziaferi V, et al. 2012 Genetic overlap in Kallmann syndrome, combined pituitary hormone deficiency, and septo-optic dysplasia. Journal of Clinical Endocrinology & Metabolism 97 E694-E699.
184. Ramsay D, Kellett E, McVey M, Rees S & Milligan G 2002 Homo-and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochemical Journal 365 429-440. (doi:10.1042/ bj20020251)
185. Rashid AJ, So CH, Kong MM, Furtak T, El-Ghundi M, Cheng R, O'Dowd BF & George SR 2007 D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. PNAS 104 654-659. (doi:10.1073/pnas.0604049104)
186. Raymond JR 1995 Multiple mechanisms of receptor-G protein signaling specificity. American Journal of Physiology 269 F141-F158.
187. Rediger A, Tarnow P, Bickenbach A, Schaefer M, Krude H, Gruters A & Biebermann H 2009 Heterodimerization of hypothalamic G-proteincoupled receptors involved in weight regulation. Obesity Facts 2 80-86. (doi:10.1159/000209862)
188. Rediger A, Piechowski CL, Yi CX, Tarnow P, Strotmann R, Gruters A, Krude H, Schoneberg T, Tschop MH, Kleinau G, et al. 2011 Mutually opposite signal modulation by hypothalamic heterodimerization of ghrelin and melanocortin-3 receptors. Journal of Biological Chemistry 286 39623-39631. (doi:10.1074/jbc.M111.287607)
189. Rediger A, Piechowski CL, Habegger K, Gruters A, Krude H, Tschop MH, Kleinau G & Biebermann H 2012 MC4R Dimerization in the paraventricular nucleus and GHSR/MC3R heterodimerization in the arcuate nucleus: is there relevance for body weight regulation. Neuroendocrinology 95 277-288. (doi:10.1159/000334903)
190. Regard JB, Sato IT & Coughlin SR 2008 Anatomical profiling of G protein-coupled receptor expression. Cell 135 561-571. (doi:10.1016/j.cell.2008.08.040)
191. Reynaud R, Jayakody SA, Monnier C, Saveanu A, Bouligand J, Guedj AM, Simonin G, Lecomte P, Barlier A, Rondard P, et al. 2012 PROKR2 variants in multiple hypopituitarism with pituitary stalk interruption. Journal of Clinical Endocrinology & Metabolism 97 E1068-E1073.
192. Rios C, Gomes I & Devi LA 2006 mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. British Journal of Pharmacology 148 387-395. (doi:10.1038/sj.bjp.0706757)
193. Ritter SL & Hall RA 2009 Fine-tuning of GPCR activity by receptorinteracting proteins. Nature Reviews Molecular Cell Biology 10 819-830. (doi:10.1038/nrm2803)
194. Rivero-Muller A, Chou YY, Ji I, Lajic S, Hanyaloglu AC, Jonas K, Rahman N, Ji TH & Huhtaniemi I 2010 Rescue of defective G protein-coupled receptor function in vivo by intermolecular cooperation. PNAS 107 2319-2324. (doi:10.1073/pnas.0906695106)
195. Romero-Fernandez W, Borroto-Escuela DO, Agnati LF & Fuxe K 2013 Evidence for the existence of dopamine d2-oxytocin receptor heteromers in the ventral and dorsal striatum with facilitatory receptor-receptor interactions. Molecular Psychiatry 18 849-850. (doi:10.1038/mp.2012.103)
196. Rosenbaum DM, Rasmussen SG & Kobilka BK 2009 The structure and function of G-protein-coupled receptors. Nature 459 356-363. (doi:10.1038/nature08144)
197. Rozenfeld R & Devi LA 2011 Exploring a role for heteromerization in GPCR signalling specificity. Biochemical Journal 433 11-18. (doi:10.1042/BJ20100458)
198. Sakai T, Aoyama M, Kusakabe T, Tsuda M & Satake H 2008 Functions of a GnRH receptor heterodimer of the ascidian, Ciona intestinalis. Acta Biologica Hungarica 59 (Supplement) 241-243. (doi:10.1556/ ABiol.59.2008.Suppl.34)
199. Sakai T, Aoyama M, Kawada T, Kusakabe T, Tsuda M & Satake H 2012 Evidence for differential regulation of GnRH signaling via heterodimerization among GnRH receptor paralogs in the protochordate, Ciona intestinalis. Endocrinology 153 1841-1849. (doi:10.1210/en.2011-1668)
200. Satake H, Matsubara S, Aoyama M, Kawada T & Sakai T 2013 GPCR heterodimerization in the reproductive system: functional regulation and implication for biodiversity. Frontiers in Endocrinology 4 100.
201. Sbai O, Monnier C, Dode C, Pin JP, Hardelin JP & Rondard P 2014 Biased signaling through G-protein-coupled PROKR2 receptors harboring missense mutations. FASEB Journal 28 3734-3744. (doi:10.1096/fj.13-243402)
202. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, Choe HW, Hofmann KP & Ernst OP 2008 Crystal structure of opsin in its G-protein-interacting conformation. Nature 455 497-502. (doi:10.1038/nature07330)
203. Scheerer P, Heck M, Goede A, Park JH, Choe HW, Ernst OP, Hofmann KP & Hildebrand PW 2009 Structural and kinetic modeling of an activating helix switch in the rhodopsin-transducin interface. PNAS 106 10660-10665. (doi:10.1073/pnas.0900072106)
204. Schellekens H, van Oeffelen WE, Dinan TG & Cryan JF 2013 Promiscuous dimerization of the growth hormone secretagogue receptor (GHS-R1a) attenuates ghrelin-mediated signaling. Journal of Biological Chemistry 288 181-191. (doi:10.1074/jbc. M112.382473)
205. Schelshorn D, Joly F, Mutel S, Hampe C, Breton B, Mutel V & Lutjens R 2012 Lateral allosterism in the glucagon receptor family: glucagonlike peptide 1 induces G-protein-coupled receptor heteromer formation. Molecular Pharmacology 81 309-318. (doi:10.1124/ mol.111.074757)
206. Schertler GF 2008 Signal transduction: the rhodopsin story continued. Nature 453 292-293. (doi:10.1038/453292a)
207. Schlyer S & Horuk R 2006 I want a new drug: G-protein-coupled receptors in drug development. Drug Discovery Today 11 481-493. (doi:10.1016/j.drudis.2006.04.008)
208. Schoneberg T, Schulz A, Biebermann H, Hermsdorf T, Rompler H & Sangkuhl K 2004 Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacology & Therapeutics 104 173-206.
209. Schwartz TW, Frimurer TM, Holst B, Rosenkilde MM & Elling CE 2006 Molecular mechanism of 7TM receptor activation-a global toggle switch model. Annual Review of Pharmacology and Toxicology 46 481-519. (doi:10.1146/annurev.pharmtox.46.120604.141218)
210. Seeman P, Weinshenker D, Quirion R, Srivastava LK, Bhardwaj SK, Grandy DK, Premont RT, Sotnikova TD, Boksa P, El-Ghundi M, et al. 2005 Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. PNAS 102 3513-3518. (doi:10.1073/pnas.0409766102)
211. Seeman P, Ko F, Jack E, Greenstein R & Dean B 2007 Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in postmortem schizophrenia brain. Synapse 61 303-309.
212. Seifert R & Wenzel-Seifert K 2002 Constitutive activity of G-proteincoupled receptors: cause of disease and common property of wildtype receptors. Naunyn-Schmiedebergs Archives of Pharmacology 366 381-416. (doi:10.1007/s00210-002-0588-0)
213. Shoichet BK & Kobilka BK 2012 Structure-based drug screening for G-protein-coupled receptors. Trends in Pharmacological Sciences 33 268-272. (doi:10.1016/j.tips.2012.03.007)
214. Shonberg J, Scammells PJ & Capuano B 2011 Design strategies for bivalent ligands targeting GPCRs. ChemMedChem 6 963-974. (doi:10.1002/cmdc.201100101)
215. Skieterska K, Duchou J, Lintermans B & Van Craenenbroeck K 2013 Detection of G protein-coupled receptor (GPCR) dimerization by coimmunoprecipitation. Methods in Cell Biology 117 323-340. (doi:10.1016/B978-0-12-408143-7.00017-7)
216. Smith NJ & Milligan G 2010 Allostery at G protein-coupled receptor homo-and heteromers: uncharted pharmacological landscapes. Pharmacological Reviews 62 701-725. (doi:10.1124/pr.110.002667)
217. Smit MJ, Vischer HF, Bakker RA, Jongejan A, Timmerman H, Pardo L & Leurs R 2007 Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity. Annual Review of Pharmacology and Toxicology 47 53-87. (doi:10.1146/annurev. pharmtox.47.120505.105126)
218. Smits G, Olatunbosun O, Delbaere A, Pierson R, Vassart G & Costagliola S 2003 Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. New England Journal of Medicine 349 760-766. (doi:10.1056/NEJMoa030064)
219. Song GJ & Hinkle PM 2005 Regulated dimerization of the thyrotropinreleasing hormone receptor affects receptor trafficking but not signaling. Molecular Endocrinology 19 2859-2870. (doi:10.1210/me.2005-0133)
220. Song GJ, Jones BW & Hinkle PM 2007 Dimerization of the thyrotropinreleasing hormone receptor potentiates hormone-dependent receptor phosphorylation. PNAS 104 18303-18308. (doi:10.1073/ pnas.0702857104)
221. Sposini S, Caltabiano G, Hanyaloglu AC & Miele R 2015 Identification of transmembrane domains that regulate spatial arrangements and activity of prokineticin receptor 2 dimers. Molecular and Cellular Endocrinology 399 362-372. (doi:10.1016/j.mce.2014.10.024)
222. Sun Y, Lu X & Gershengorn MC 2003 Thyrotropin-releasing hormone receptors-similarities and differences. Journal of Molecular Endocrinology 30 87-97. (doi:10.1677/jme.0.0300087)
223. Surgand JS, Rodrigo J, Kellenberger E & Rognan D 2006 A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins 62 509-538.
224. Svendsen AM, Vrecl M, Ellis TM, Heding A, Kristensen JB, Wade JD, Bathgate RA, De Meyts P & Nohr J 2008 Cooperative binding of insulin-like Peptide 3 to a dimeric relaxin family peptide receptor 2. Endocrinology 149 1113-1120. (doi:10.1210/en.2007-0412)
225. Svendsen AM, Vrecl M, Knudsen L, Heding A, Wade JD, Bathgate RA, De Meyts P & Nohr J 2009 Dimerization and negative cooperativity in the relaxin family peptide receptors. Annals of the New York Academy of Sciences 1160 54-59. (doi:10.1111/j.1749-6632.2009.03835.x)
226. Tadagaki K, Jockers R & Kamal M 2011 History and biological significance of GPCR heteromerization in the neuroendocrine system. Neuroendocrinology 95 223-231. (doi:10.1159/000330000)
227. Tadagaki K, Jockers R & Kamal M 2012a History and biological significance of GPCR heteromerization in the neuroendocrine system. Neuroendocrinology 95 223-231.
228. Tadagaki K, Tudor D, Gbahou F, Tschische P, Waldhoer M, Bomsel M, Jockers R & Kamal M 2012b Human cytomegalovirus-encoded UL33 and UL78 heteromerize with host CCR5 and CXCR4 impairing their HIV coreceptor activity. Blood 119 4908-4918.
229. Tao YX 2006 Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications. Pharmacology & Therapeutics 111 949-973.
230. Tao YX 2010 Mutations in the melanocortin-3 receptor (MC3R) gene: Impact on human obesity or adiposity. Current Opinion in Investigational Drugs 11 1092-1096.
231. Tao YX, Johnson NB & Segaloff DL 2004 Constitutive and agonistdependent self-association of the cell surface human lutropin receptor. Journal of Biological Chemistry 279 5904-5914. (doi:10.1074/ jbc.M311162200)
232. Tarnow P, Rediger A, Brumm H, Ambrugger P, Rettenbacher E, Widhalm K, Hinney A, Kleinau G, Schaefer M, Hebebrand J, et al. 2008 A heterozygous mutation in the third transmembrane domain causes a dominant-negative effect on signalling capability of the MC4R. Obesity Facts 1 155-162. (doi:10.1159/000138251)
233. Tate CG & Schertler GF 2009 Engineering G protein-coupled receptors to facilitate their structure determination. Current Opinion in Structural Biology 19 386-395. (doi:10.1016/j.sbi.2009.07.004)
234. Teichmann A, Rutz C, Kreuchwig A, Krause G, Wiesner B & Schulein R 2012 The pseudo signal peptide of the corticotropin-releasing factor receptor type 2A prevents receptor oligomerization. Journal of Biological Chemistry 287 27265-27274. (doi:10.1074/jbc. M112.360594)
235. Teichmann A, Gibert A, Lampe A, Grzesik P, Rutz C, Furkert J, Schmoranzer J, Krause G, Wiesner B & Schulein R 2014 The specific monomer/dimer equilibrium of the corticotropin-releasing factor receptor type 1 is established in the endoplasmic reticulum. Journal of Biological Chemistry 289 24250-24262. (doi:10.1074/jbc. M114.553644)
236. Teitler M & Klein MT 2012 A new approach for studying GPCR dimers: drug-induced inactivation and reactivation to reveal GPCR dimer function in vitro, in primary culture, and in vivo. Pharmacology & Therapeutics 133 205-217.
237. Terrillon S, Durroux T, Mouillac B, Breit A, Ayoub MA, Taulan M, Jockers R, Barberis C & Bouvier M 2003 Oxytocin and vasopressin V1a and V2 receptors form constitutive homo-and heterodimers during biosynthesis. Molecular Endocrinology 17 677-691. (doi:10.1210/me.2002-0222)
238. Terrillon S, Barberis C & Bouvier M 2004 Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with betaarrestin and their trafficking patterns. PNAS 101 1548-1553. (doi:10.1073/pnas.0305322101)
239. Themmen APN & Huhtaniemi IT 2000 Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocrine Reviews 21 551-583. (doi:10.1210/edrv.21.5.0409)
240. Tripathi A, Vana PG, Chavan TS, Brueggemann LI, Byron KL, Tarasova NI, Volkman BF, Gaponenko V & Majetschak M 2015 Heteromerization of chemokine (C-X-C motif) receptor 4 with alpha1A/B-adrenergic receptors controls alpha1-adrenergic receptor function. PNAS 112 E1659-E1668.
241. Troppmann B, Kleinau G, Krause G & Gromoll J 2013 Structural and functional plasticity of the luteinizing hormone/ choriogonadotrophin receptor. Human Reproduction Update 19 583-602. (doi:10.1093/humupd/dmt023)
242. Tschische P, Tadagaki K, Kamal M, Jockers R & Waldhoer M 2011 Heteromerization of human cytomegalovirus encoded chemokine receptors. Biochemical Pharmacology 82 610-619. (doi:10.1016/j. bcp.2011.06.009)
243. Tyndall JD & Sandilya R 2005 GPCR agonists and antagonists in the clinic. Medicinal Chemistry 1 405-421. (doi:10.2174/ 1573406054368675)
244. Uberti MA, Hague C, Oller H, Minneman KP & Hall RA 2005 Heterodimerization with beta2-adrenergic receptors promotes surface expression and functional activity of alpha1D-adrenergic receptors. Journal of Pharmacology and Experimental Therapeutics 313 16-23.
245. Uddin MS, Kim H, Deyo A, Naider F & Becker JM 2012 Identification of residues involved in homodimer formation located within a betastrand region of the N-terminus of a Yeast G protein-coupled receptor. Journal of Receptors and Signal Transduction Research 32 65-75. (doi:10.3109/10799893.2011.647352)
246. Urizar E, Montanelli L, Loy T, Bonomi M, Swillens S, Gales C, Bouvier M, Smits G, Vassart G & Costagliola S 2005 Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO Journal 24 1954-1964. (doi:10.1038/ sj.emboj.7600686)
247. van Unen J, Woolard J, Rinken A, Hoffmann C, Hill SJ, Goedhart J, Bruchas MR, Bouvier M & Adjobo-Hermans MJ 2015 A perspective on studying G-protein-coupled receptor signaling with resonance energy transfer biosensors in living organisms. Molecular Pharmacology 88 589-595. (doi:10.1124/mol.115.098897)
248. Vassart G & Costagliola S 2011 G protein-coupled receptors: mutations and endocrine diseases. Nature Reviews Endocrinology 7 362-372. (doi:10.1038/nrendo.2011.20)
249. Vassart G & Kleinau G 2014 TSH receptor mutations and diseases. In Endotext. Eds LJ De Groot, P Beck-Peccoz, G Chrousos, K Dungan, A Grossman, JM Hershman, C Koch, R McLachlan, M New, R Rebar, et al. South Dartmouth, MA, USA: MDText.com, Inc.
250. Veldhuis NA, Poole DP, Grace M, McIntyre P & Bunnett NW 2015 The G protein-coupled receptor-transient receptor potential channel axis: molecular insights for targeting disorders of sensation and inflammation. Pharmacological Reviews 67 36-73.
251. Vidi PA & Watts VJ 2009 Fluorescent and bioluminescent proteinfragment complementation assays in the study of G protein-coupled receptor oligomerization and signaling. Molecular Pharmacology 75 733-739. (doi:10.1124/mol.108.053819)
252. Viero C, Shibuya I, Kitamura N, Verkhratsky A, Fujihara H, Katoh A, Ueta Y, Zingg HH, Chvatal A, Sykova E, et al. 2010 REVIEW: oxytocin: crossing the bridge between basic science and pharmacotherapy. CNS Neuroscience & Therapeutics 16 e138-156.
253. Vilardaga JP, Nikolaev VO, Lorenz K, Ferrandon S, Zhuang Z & Lohse MJ 2008 Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling. Nature Chemical Biology 4 126-131. (doi:10.1038/nchembio.64)
254. Waldhoer M, Fong J, Jones RM, Lunzer MM, Sharma SK, Kostenis E, Portoghese PS & Whistler JL 2005 A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. PNAS 102 9050-9055. (doi:10.1073/pnas.0501112102)
255. Walther C & Ferguson SS 2015 Minireview: role of intracellular scaffolding proteins in the regulation of endocrine G proteincoupled receptor signaling. Molecular Endocrinology 29 814-830. (doi:10.1210/me.2015-1091)
256. Wess J 1998 Molecular basis of receptor/G-protein-coupling selectivity. Pharmacology & Therapeutics 80 231-264.
257. Whistler JL, Enquist J, Marley A, Fong J, Gladher F, Tsuruda P, Murray SR & Von Zastrow M 2002 Modulation of postendocytic sorting of G proteincoupled receptors. Science 297 615-620. (doi:10.1126/science.1073308)
258. White JF, Grodnitzky J, Louis JM, Trinh LB, Shiloach J, Gutierrez J, Northup JK & Grisshammer R 2007 Dimerization of the class A G protein-coupled neurotensin receptor NTS1 alters G protein interaction. PNAS 104 12199-12204. (doi:10.1073/pnas.0705312104)
259. Whorton MR, Bokoch MP, Rasmussen SG, Huang B, Zare RN, Kobilka B & Sunahara RK 2007 A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. PNAS 104 7682-7687. (doi:10.1073/pnas.0611448104)
260. Wichard JD, Ter Laak A, Krause G, Heinrich N, Kuhne R & Kleinau G 2011 Chemogenomic analysis of G-protein coupled receptors and their ligands deciphers locks and keys governing diverse aspects of signalling. PLoS ONE 6 e16811.
261. Wilson SJ, McGinley K, Huang AJ & Smyth EM 2007 Heterodimerization of the alpha and beta isoforms of the human thromboxane receptor enhances isoprostane signaling. Biochemical and Biophysical Research Communications 352 397-403. (doi:10.1016/j.bbrc.2006.11.040)
262. Wrzal PK, Devost D, Petrin D, Goupil E, Iorio-Morin C, Laporte SA, Zingg HH & Hebert TE 2012a Allosteric interactions between the oxytocin receptor and the beta2-adrenergic receptor in the modulation of ERK1/2 activation are mediated by heterodimerization. Cell Signaling 24 342-350.
263. Wrzal PK, Goupil E, Laporte SA, Hebert TE & Zingg HH 2012b Functional interactions between the oxytocin receptor and the beta2-adrenergic receptor: implications for ERK1/2 activation in human myometrial cells. Cell Signaling 24 333-341.
264. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC, et al. 2010 Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330 1066-1071. (doi:10.1126/science.1194396)
265. Wu H, Wacker D, Mileni M, Katritch V, Han GW, Vardy E, Liu W, Thompson AA, Huang XP, Carroll FI, et al. 2012 Structure of the human kappa-opioid receptor in complex with JDTic. Nature 485 327-332. (doi:10.1038/nature10939)
266. Xie Z, Westmoreland SV & Miller GM 2008 Modulation of monoamine transporters by common biogenic amines via trace amine-associated receptor 1 and monoamine autoreceptors in human embryonic kidney 293 cells and brain synaptosomes. Journal of Pharmacology and Experimental Therapeutics 325 629-640. (doi:10.1124/ jpet.107.135079)
267. Yanagawa M, Yamashita T & Shichida Y 2011 Comparative fluorescence resonance energy transfer analysis of metabotropic glutamate receptors: implications about the dimeric arrangement and rearrangement upon ligand bindings. Journal of Biological Chemistry 286 22971-22981. (doi:10.1074/jbc.M110.206870)
268. Yekkirala AS 2013 Two to tango: GPCR oligomers and GPCR-TRP channel interactions in nociception. Life Sciences 92 438-445. (doi:10.1016/j.lfs.2012.06.021)
269. Young SF, Griffante C & Aguilera G 2007 Dimerization between vasopressin V1b and corticotropin releasing hormone type 1 receptors. Cellular and Molecular Neurobiology 27 439-461. (doi:10.1007/s10571-006-9135-8)
270. Yuan Y, Arnatt CK, El-Hage N, Dever SM, Jacob JC, Selley DE, Hauser KF & Zhang Y 2013 A bivalent ligand targeting the putative mu opioid receptor and chemokine receptor CCR5 heterodimers: binding affinity versus functional activities. MedChemComm 4 847-851. (doi:10.1039/c3md00080j)
271. Zhao Q & Wu BL 2012 Ice breaking in GPCR structural biology. Acta Pharmacologica Sinica 33 324-334. (doi:10.1038/aps.2011.187)
272. Zhou W, Li JD, Hu WP, Cheng MY & Zhou QY 2012 Prokineticin 2 is involved in the thermoregulation and energy expenditure. Regulatory Peptides 179 84-90. (doi:10.1016/j.regpep.2012.08.003)
273. Zhu X & Wess J 1998 Truncated V2 vasopressin receptors as negative regulators of wild-type V2 receptor function. Biochemistry 37 15773-15784. (doi:10.1021/bi981162z)
274. Zhu CC, Cook LB & Hinkle PM 2002 Dimerization and phosphorylation of thyrotropin-releasing hormone receptors are modulated by agonist stimulation. Journal of Biological Chemistry 277 28228-28237. (doi:10.1074/jbc.M204221200)
275. Zoenen M, Urizar E, Swillens S, Vassart G & Costagliola S 2012 Evidence for activity-regulated hormone-binding cooperativity across glycoprotein hormone receptor homomers. Nature Communications 3 1007. (doi:10.1038/ncomms1991)